Alembic Pharmaceuticals receives USFDA approval for Macitentan Tablets, 10 mg
Alembic Pharmaceuticals secures final approval for its ANDA Macitentan Tablets, a therapeutic equivalent of Actelion’s Opsumit,…
Sign in
Sign in
Recover your password.
A password will be e-mailed to you.
HiMedia Laboratories receives CDSCO approval for Hepatitis B and C Molecular Diagnostic Kits
The Hi-PCR® Hepatitis B and C detection and quantitation kits will now be manufactured in India under CDSCO approval, supporting…
Alkem Laboratories launches Olesoft Trucera moisturising lotion to strengthen skin barrier
Olesoft Trucera contains ceramides, N-Palmitoyl Serinol, dual oat-extract actives and Niacinamide; available on prescription…
Disruption to traditional distribution channels to hinder pharma companies from adopting Trump’s DTC…
GlobalData highlights patient awareness gaps, operational demands, and disrupted supply chains as key barriers to US pharma…
BRAND GMBH + CO KG launches Transferpette pro micropipette in India
The new Transferpette® pro expands the Transferpette S lineup with added flexibility, user adjustment features, and broader volume…
DKMS opens applications for 2026 John Hansen Research Grant in stem cell transplantation and cell…
Up to four young scientists will receive €240,000 each over three years for research on haematopoietic stem cell transplantation…
Glenmark Pharmaceuticals to launch Micafungin for Injection USP in the United States
The company will distribute Micafungin for Injection USP, 50 mg/vial and 100 mg/vial (Single-Dose Vial), beginning September 2025
Reshaping healthcare: The convergence of digital therapeutics and point-of-care diagnostics
As digital tools evolve, the integration of Digital Therapeutics and Point-of-Care diagnostics is transforming how care is…
Advancing Nitrosamine Control: A Strategic Path to Regulatory Confidence and Safer Medicines
Webinar | 7th August 2025 | 60 mins
Anil Matai, Director General of OPPI, on the Future of Indian Pharma: From Product Provider to…
Regulatory Watch: Anil Matai, Director General of OPPI